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MeBACKGROUND Bifurcation lesions are frequent among patients with symptomatic coronary disease treated by
percutaneous coronary intervention. Current evidence recommends a conservative (provisional) approach when treating
the side branch (SB).
OBJECTIVES The TRYTON (Prospective, Single Blind, Randomized Controlled Study to Evaluate the Safety & Effec-
tiveness of the Tryton Side Branch Stent Used With DES in Treatment of de Novo Bifurcation Lesions in the Main Branch &
Side Branch in Native Coronaries) bifurcation trial sought to compare treatment of de novo true bifurcation lesions using a
dedicated bifurcation stent or SB balloon angioplasty.
METHODS We randomly assigned patients with true bifurcation lesions to a main vessel stent plus provisional stenting
or the bifurcation stent. The primary endpoint (powered for noninferiority) was target vessel failure (TVF) (cardiac death,
target vessel myocardial infarction, and target vessel revascularization). The secondary angiographic endpoint (powered
for superiority) was in-segment percent diameter stenosis of the SB at 9 months.
RESULTS We randomized 704 patients with bifurcation coronary lesions at 58 centers (30 from Europe and 28 from the
United States). At 9 months, TVF was 17.4% in the bifurcation stent group compared with 12.8% in the provisional group
(p ¼ 0.11), mainly because of a higher periprocedural myocardial infarction rate (13.6% vs. 10.1%, p ¼ 0.19). The TVF
difference of þ4.6% (2-sided 95% conﬁdence interval: 1.0 to 10.3; upper limit of the 1-sided 95% conﬁdence interval:
10.3) was not within the pre-speciﬁed noninferiority margin of 5.5% (p ¼ 0.42 for noninferiority). The SB in-segment
diameter stenosis among the angiographic cohort was lower in the bifurcation stent group compared with the provisional
group (31.6% vs. 38.6%, p ¼ 0.002 for superiority), with no difference in binary restenosis rates (diameter stenosis
$50%) at 9 months follow-up (22.6% vs. 26.8%, p ¼ 0.44).
CONCLUSIONS Provisional stenting should remain the preferred strategy for treatment of non–left main true coronary
bifurcation lesions. (Prospective, Single Blind, Randomized Controlled Study to Evaluate the Safety & Effectiveness of the
Tryton Side Branch Stent Used With DES in Treatment of de Novo Bifurcation Lesions in the Main Branch & Side Branch in
Native Coronaries [TRYTON]; NCT01258972) (J Am Coll Cardiol 2015;65:533–43) © 2015 by the American College of
Cardiology Foundation.m the *Columbia University Medical Center/New York Presbyterian Hospital, New York, New York; yCardiovascular Research
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CK = creatine kinase
DES = drug-eluting stent(s)
MB = main branch
MI = myocardial infarction
PCI = percutaneous
coronary intervention
QCA = quantitative
coronary angiography
SB = side branch
TVF = target vessel failure
TVR = target vessel
revascularization
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B ifurcation lesions are frequent amongpatients presenting with symptom-atic coronary disease and undergoing
percutaneous coronary intervention (PCI),
accounting for approximately 15% to 20%
of the lesions treated by PCI (1). Despite
major advancements in stent technology,
bifurcation lesions are still challenging for
interventional cardiologists and treatment is
associated with increased periprocedural
myocardial infarction (MI), stent thrombosis,
long-term restenosis, and cost (2,3). Although
many techniques and strategies have been
proposed (4–10), the conservative (provi-
sional) approach, where the main branch(MB) is treated ﬁrst and the side branch (SB) is only
treated if required, remains the current standard of
therapy (2,3,11–14). However, enrollment bias, small
sample sizes, heterogeneous PCI techniques, and the
lack of rigorous endpoints have complicated deﬁni-
tive conclusions in prior studies. Recently, several
small nonrandomized studies showed initial favor-
able outcomes for a dedicated bifurcation stent, a
bare-metal stent designed to secure and treat the
bifurcation SB (15–19). The TRYTON (Prospective,
Single Blind, Randomized Controlled Study to Eval-
uate the Safety & Effectiveness of the Tryton Side
Branch Stent Used With DES in Treatment of de
Novo Bifurcation Lesions in the Main Branch &
Side Branch in Native Coronaries) bifurcation trial
was a prospective, multicenter, single-blind, random-
ized, controlled study evaluating the bifurcation
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PATIENT SELECTION. The TRYTON study enrolled
patients with symptoms or objective evidence of
ischemia due to a signiﬁcant ($50% narrowing by
visual assessment) true bifurcation lesion (Medina
classiﬁcation 1,1,1; 1,0,1; or 0,1,1) (20) located in a
de novo native coronary artery with an SB from
$2.5 mm to #3.5 mm in diameter and an MB
from $2.5 mm to #4.0 mm in diameter. Lesion length
was #28 mm in the MB (treatable with a single stent)
and #5 mm in the SB. The MB and SB (when required)
were treated with DES commercially available in the
United States.
Important exclusion criteria were as follows:
ST-segment elevation MI within 72 h or non–ST-
segment elevation MI within 7 days preceding the
index procedure; left ventricular ejection fraction
<30%; impaired renal function (serum creatinine
>2.5 mg/dl or 221 mmol/l) or on dialysis; left main
coronary artery disease (protected and unprotected);
trifurcation lesions; total occlusion of the target
vessel; severely calciﬁed lesion(s); the presence of
excessive tortuosity; and angiographic evidence of
thrombus. The complete list of inclusion and exclu-
sion criteria is provided in Online Table 1.
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535Carolina) is a dedicated SB non-DES composed of a
cobalt chromium alloy with 3 zones: an SB zone (5.5 to
6.5 mm) deployed within the SB; a transition zone
(4.5 mm) at the SB ostium; and an MB zone (8 mm)
(Online Figure 1).
The implantation technique involves lesion prepa-
ration (pre-dilation of MB and SB), placement of the
bifurcation stent into the SB, and placement of a
commercially available DES within the MB. Simulta-
neous or sequential ﬁnal kissing balloon inﬂation is
then performed. Patients randomized to the provi-
sional PCI strategy underwent PCI per standard
operator technique, with ﬁnal kissing balloon post-
dilation. For both groups, implantation of an un-
planned additional stent inside the SB was allowed
only in cases of Thrombolysis In Myocardial Infarction
ﬂow grade <3, dissection type B or greater, or residual
stenosis >80%. Pre-procedure and post-procedure
dual antiplatelet therapy were recommended to con-
form to the American Heart Association/American
College of Cardiology/Society for Cardiovascular
Angiography and Interventions joint guidelines for
PCI (13).
STUDY DESIGN AND OVERSIGHT. The TRYTON trial
was a prospective, multicenter, randomized, single-
blind, controlled clinical trial. The overall study
design is shown in Figure 1. After completion of the
diagnostic angiogram and conﬁrmation of subject
eligibility, patients were randomly assigned with the
use of a computer-generated scheme, blocked sepa-
rately at each participating site, and stratiﬁed by MB
drug-eluting use and clinical site. The institutional
review board at each participating site approved the
TRYTON trial, and all patients provided written
informed consent. The sponsor (Tryton Medical, Inc.)
and the members of the executive committee
designed the trial. The sponsor funded the study and
participated in site selection and management. Data
collection and monitoring were performed by an in-
dependent third-party contract research organization.
The executive committee met regularly in person to
monitor all aspects of the conduct of the trial.
DATA MANAGEMENT. An independent clinical events
committee adjudicated all serious adverse events
(Harvard Cardiovascular Research Institute, Boston,
Massachusetts). A data and safety monitoring board
met frequently and had access to all study data
and treatment assignments when requested. All data
were sent for analysis to independent consulting
biostatisticians. An independent angiographic core
laboratory (Cardiovascular Research Foundation,
New York, New York) analyzed all baseline, follow-
up, and event angiograms. Online Table 2 lists themembers of the committees, the institutions, and the
research organizations participating in the TRYTON
trial.
STUDY ENDPOINTS. The primary endpoint (powered
for noninferiority) at 9-month follow-up was the rate
of target vessel failure (TVF) deﬁned as the composite
of cardiac death, target vessel MI (Q-wave or non–
Q-wave [3  upper limit of normal creatine kinase
{CK}-MB]), and clinically driven target vessel revas-
cularization (TVR) in the MB or SB. The secondary
angiographic endpoint (powered for superiority) was
the SB in-segment percent diameter stenosis of the
bifurcation stent compared with SB balloon angio-
plasty at the 9-month follow-up. Pre-speciﬁed addi-
tional clinical secondary endpoints included the
following: the rates of device success (<30% residual
stenosis within the SB), lesion success (<50% residual
stenosis using any percutaneous method), and pro-
cedural success (lesion success without the occur-
rence of in-hospital major adverse cardiac events
[death, MI, emergent coronary artery bypass graft,
clinically driven target lesion revascularization]); the
rate of all-cause and cardiac mortality; the rate of
Academic Research Consortium–deﬁned stent
thrombosis (21); and the rate of target lesion revas-
cularization. Important endpoints are speciﬁcally
deﬁned in Online Table 3. All patients were followed
clinically during the index hospitalization, at 30 days,
6 months, 9 months, and then annually up to 5 years.
STATISTICAL ANALYSIS. For the primary endpoint,
we estimated that with a sample of 664 patients, the
study would have at least 81% power to show non-
inferiority of the bifurcation stent compared with the
standard provisional approach, assuming the rate of
TVF at 9 months would be 13% in the provisional
group and 11% in the bifurcation stent group, with a
margin for noninferiority of 5.5% and using a 1-sided
binomial test of proportions with a signiﬁcance level
of a ¼ 0.025. The number was increased to 704
patients to account for an expected 6% loss to
follow-up.
For the secondary angiographic endpoint, we
estimated that with a sample of 318 patients, the
study would have at least 90% power to show the
superiority of the bifurcation stent compared with
the standard provisional approach, assuming that
9-month in-segment SB percent diameter stenosis
would be reduced by 8% (from 31% in the provisional
treatment group to 23% in the bifurcation stent
group), assuming an SD of 22% in both arms and using
a 2-sided t test with a signiﬁcance level of a ¼ 0.05.
This number was increased to 374 patients (187 per
arm) to account for an expected 15% loss to
FIGURE 1 Patient Flow Chart and Enrollment
Assessed for eligibility (n=2465)
Lost to follow-up (n=6)
Withdrawal of study (n=5)
Lost to follow-up (n=4)
Withdrawal of study (n=2)
Death (n=4)Death (n=4)
Clinical 9 month follow-up (n=334)
Angiographic 9-month follow-up (n=168)
Clinical 9-month follow-up (n=345)
Angiographic 9-month follow-up (n=158)
Excluded (n=1761)
Angiographic exclusion criteria (n=1135)
Clinical exclusion criteria (n=508)


Randomized (n=704)
Angiographic cohort (n=374)
Allocated to provisional stenting (n=349)
Received provisional stenting (n=347)
Received Tryton bifurcation stent (n=2)


Received Tryton bifurcation stent (n=341)
Did not receive Tryton bifurcation stent (n=14)
-Stent dislodgement before reaching target
lesion (n=6),
-Failure to wire side branch (n=2)
-Failure to cross lesion with stent (n=2)
-Side branch not suitable for stenting (n=2)
-Randomization error (n=2)
Allocated to Tryton bifurcation stent (n=355)


Intention-to-treat population. Clinical follow-up at 9months was 97%, and angiographic follow-up (pre-speciﬁed cohort) at 9months was 87%.
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536angiographic follow-up. An exploratory post-hoc
analysis was performed to evaluate the presence of
a signiﬁcant interaction between the primary
endpoint and its components and the vessel diameter
of the SB at baseline. Categoric variables were
compared using the Fisher exact test. Continuous
variables, which are presented as mean  SD, were
compared using the Student t test. All analyses wereperformed with data from the intention-to-treat
population, which included all patients who under-
went randomization regardless of the treatment
actually received. Survival curves for time-to-event
variables were constructed on the basis of all avail-
able follow-up data using Kaplan-Meier estimates and
compared using the log-rank test. A 2-sided alpha
level of 0.05 was used for all superiority testing. All
TABLE 1 Baseline Clinical Characteristics of Randomized Patients
Tryton Stent
(N ¼ 355)
Provisional
(N ¼ 349) p Value
Age, yrs 64.5  10.6 64.6  9.4 0.92
Male 255/355 (71.8) 256/349 (73.4) 0.67
Smoking history 0.62
Current smoker 62/355 (17.5) 53/348 (15.2)
Former smoker 123/355 (34.6) 125/348 (35.9)
Never 170/355 (47.9) 170/348 (48.9)
Diabetes mellitus 85/355 (23.9) 98/349 (28.1) 0.23
Hypertension 260/355 (73.2) 256/348 (73.6) 0.93
Hyperlipidemia 260/351 (74.1) 266/344 (77.3) 0.33
Family history of premature CAD 114/309 (36.9) 101/311 (32.5) 0.27
Prior MI 105/350 (30.0) 131/347 (37.8) 0.03
Prior PCI 135/355 (38.0) 146/349 (41.8) 0.32
Prior CABG 9/353 (2.5) 7/349 (2.0) 0.80
History of congestive heart failure 6/355 (1.7) 3/349 (0.9) 0.51
Prior stroke 8/350 (2.3) 13/343 (3.8) 0.28
Prior transient ischemic attack 10/351 (2.8) 8/346 (2.3) 0.81
Renal insufﬁciency on dialysis 0/355 (0.0) 1/348 (0.3%) 0.49
Atrial ﬁbrillation 38/354 (10.7) 24/348 (6.9) 0.08
Mean left ventricular ejection
fraction, %
57.7  9.6 57.5  9.9 0.81
Clinical presentation 0.94
Stable angina 262/355 (73.8) 261/349 (74.8)
ACS-UA 71/355 (20.0) 69/349 (19.8)
Silent ischemia 20/355 (5.6) 18/349 (5.2)
No angina 2/355 (0.6) 1/349 (0.3)
Functional test showing ischemia 126/201 (62.7) 117/185 (63.2) 0.92
Access site 0.60
Femoral 231/355 (65.1) 225/349 (64.5)
Radial 123/355 (34.6) 124/349 (35.5)
Other 1/355 (0.3) 0/349 (0.0)
Number of vessels with $50%
stenosis*
0.12
1-vessel disease 239/355 (67.3) 217/349 (62.2)
2-vessel disease 98/355 (27.6) 105/349 (30.1)
3-vessel disease 18/355 (5.1) 27/349 (7.7)
Medina classiﬁcation (site reported)* 0.51
1,1,1 260/355 (73.2) 239/348 (68.7)
1,0,1 41/355 (11.5) 43/348 (12.4)
0,1,1 52/355 (14.6) 65/348 (18.7)
1,1,0 or 1,0,0 or 0,1,0 or 0,0,1† 2/355 (0.6) 1/348 (0.3)
Antiplatelet therapy pre-loading
before index procedure
298/355 (83.9) 299/349 (85.7) 0.53
Values are mean  SD or n/N (%). *Site reported. †Not true bifurcation.
ACS-UA ¼ acute coronary syndrome-unstable angina; CABG ¼ coronary artery bypass graft; CAD ¼ coronary
artery disease; MI ¼ myocardial infarction; PCI ¼ percutaneous coronary intervention.
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537statistical analyses were performed using SAS soft-
ware, version 9.2 (SAS Institute, Inc., Cary, North
Carolina).
RESULTS
PATIENTS AND ENROLLMENT. Between December
17, 2010, and November 20, 2012, a total of 704 pa-
tients with angina and/or ischemia involving a true
coronary bifurcation lesion were enrolled at 58 sites
(30 in Europe and 28 in the United States) and were
randomly assigned to the provisional strategy
(n ¼ 349) or the bifurcation stent strategy (n ¼ 355).
All patients were followed for at least 9 months
(median follow-up period, 366 days; range 4 to 840
days). Clinical and angiographic (pre-speciﬁed
angiographic cohort) follow-up was obtained in 97%
and 87% of patients, respectively (Figure 1). The
baseline characteristics of the patients in the 2 groups
were generally well balanced (Table 1). True bifurca-
tion lesions, which were visually assessed by site
operators as $50% diameter stenosis in both the SB
and either the proximal or distal MB (Medina classi-
ﬁcation 1,1,1; 1,0,1; and 0,1,1), were present in all but 3
patients (0.4%; 2 in the bifurcation stent group and 1
in the provisional group) (Online Figure 2A), with no
difference between groups in the type of bifurcation.
When assessed by the angiographic core labora-
tory, true bifurcations at randomization were present
in 88.1% of the entire cohort (bifurcation stent group:
89.9%, provisional group: 86.2%) (Online Figure 2B),
with no difference between groups in the type of
bifurcation. Among the entire cohort, bifurcation le-
sions involved the left descending artery and diago-
nal branches in 75.8% of cases; the left circumﬂex,
marginal, or ramus branches in 18.2% of cases; and
the right coronary artery in 6.0% of cases, with no
difference between groups. On angiography, no major
differences were seen in the MB lesions between both
groups; however, lesions in the SB from the bifurca-
tion stent group were, on average, slightly more
severe (diameter stenosis 58.0% vs. 54.0%, p < 0.001)
and longer (4.8 vs. 4.4 mm, p < 0.001) (Table 2).
PROCEDURAL OUTCOMES. Of the 355 patients
assigned to the bifurcation stent group, 341 (96.1%)
received the study stent in the SB. Reasons for the
bifurcation stent not being implanted were the
following: stent dislodgment of balloon before
reaching target lesion (n ¼ 6); failure of the coronary
wire to cross the target lesion (n ¼ 2); failure of the
stent to cross the target lesion (n ¼ 2); SB not suitable
for stenting (occlusive dissection with wire and SB
deemed too small for stenting) (n ¼ 2); and random-
ization error (n ¼ 2). No patients died during or within30 days of the procedure in either group. Nontarget
lesions (other than the index bifurcation lesion) were
treated in 43 patients (12.1%) and 59 patients (16.9%)
in the bifurcation stent and provisional groups,
respectively. Additional stents in the SB for bailout
situations (dissection type B or greater, Thrombolysis
In Myocardial Infarction ﬂow grade <3, or residual
stenosis >80%) were more frequent in the provisional
TABLE 2 Quantitative and Qualitative Angiographic Findings at Baseline
and After Procedure
Tryton Stent
(N ¼ 355)
Provisional
(N ¼ 349) p Value
Main branch
Baseline
Reference vessel diameter, mm 2.91  0.36 2.91  0.35 0.82
Minimal lumen diameter, mm 0.99  0.37 1.01  0.35 0.51
Diameter stenosis, % 66.16  11.87 65.46  11.10 0.42
Lesion length, mm 16.8  7.3 16.0  6.8 0.11
Thrombus 3/354 (0.8) 4/349 (1.1) 0.72
Tortuosity 0.007
Moderate 0/354 (0.0) 5/349 (1.4)
Severe 0/354 (0.0) 2/349 (0.6)
Calciﬁcation 0.04
Moderate 48/354 (13.6) 59/349 (16.9)
Severe 10/354 (2.8) 19/349 (5.4)
Post-procedure
Reference vessel diameter, mm 2.99  0.37 2.97  0.36 0.70
In-segment minimal lumen
diameter, mm
2.34  0.37 2.36  0.36 0.52
In-segment diameter stenosis, % 21.60  7.82 20.61  8.00 0.10
In-stent minimal lumen
diameter, mm
2.71  0.38 2.70  0.34 0.79
In-stent diameter stenosis, % 9.33  7.43 8.97  7.54 0.53
In-segment acute gain, mm 1.41  0.44 1.35  0.45 0.27
In-stent acute gain, mm 1.76  0.44 1.67  0.39 0.058
Side branch
Baseline
Reference vessel diameter, mm 2.25  0.30 2.21  0.33 0.09
Minimal lumen diameter, mm 0.95  0.34 1.02  0.34 0.009
Diameter stenosis, % 58.00  14.28 54.01  14.46 <0.001
Lesion length, mm 4.8  1.6 4.4  1.1 <0.001
Thrombus 1/354 (0.3) 3/349 (0.9) 0.37
Tortuosity 0.15
Moderate 0/354 (0.0) 0/348 (0.0)
Severe 0/354 (0.0) 2/348 (0.6)
Calciﬁcation 0.81
Moderate 20/354 (5.6) 18/348 (5.0)
Severe 4/354 (1.1) 7/348 (2.0)
Angulation,  0.009
0–45 293/354 (82.8) 258/348 (74.1)
>45–90 44/354 (12.4) 74/348 (21.3)
>90 17/354 (4.8) 16/348 (4.6)
Post-procedure
Reference vessel diameter, mm 2.31  0.33 2.25  0.33 0.008
In-segment minimal lumen
diameter, mm
2.04  0.37 1.56  0.43 <0.001
In-segment diameter stenosis, % 11.98  9.64 30.51  17.19 <0.001
In-stent minimal lumen
diameter, mm
2.36  0.32 — —
In-stent diameter stenosis, % -2.21  10.12 — —
In-segment acute gain, mm 1.07  0.42 0.57  0.39 <0.001
In-stent acute gain, mm 1.38  0.43 — —
Values are mean  SD or n/N (%).
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538group (8.0%) than in the Tryton group (2.8%)
(p ¼ 0.02). There was no difference in ﬁnal balloon
post-dilation (“kissing”) between both groups (bifur-
cation stent 86.2% vs. provisional 85.1%). On average,
procedures were longer (70.5  33.1 min vs. 56.9 
31.5 min; p < 0.001) and required more contrast
(260.9  105.5 ml vs. 223.3  92.5 ml; p < 0.001) in the
bifurcation stent group. No difference in acute renal
failure was noticed between groups (bifurcation stent
0.6% vs. 0.3%). Online Table 4 shows other important
procedural and devices characteristics.
No differences were seen between groups in
the post-procedure angiographic results in the MB
(Table 2). However, patients in the bifurcation stent
group showed improved post-procedure angiographic
results in the SB, with higher in-segment acute gain
and in-segment minimal lumen diameter and lower
residual stenosis compared with the provisional
strategy. Lesion, procedure, and device success were
achieved more frequently in the bifurcation stent
group compared with the provisional group (100% vs.
88.1%, p < 0.001; 79.7% vs. 70.5%, p ¼ 0.006; and
90.8% vs. 76.8%, p < 0.001, respectively).
CLINICAL OUTCOMES AT 9 MONTHS. At 9 months
after randomization, TVF (the primary endpoint) was
17.4% in the Tryton group compared with 12.8% in the
provisional group (p ¼ 0.11). The difference of þ4.6%
(2-sided 95% conﬁdence interval: 1.0 to 10.3; upper
limit of the 1-sided 95% conﬁdence interval: 10.3) was
not within the pre-speciﬁed noninferiority margin of
5.5% (p ¼ 0.42 for noninferiority). Rates of each
component of the primary endpoint are shown in the
Central Illustration. The difference in the primary
endpoint was mainly due to a higher rate of peri-
procedural MIs (13.6% vs. 10.1%, p ¼ 0.19) after
bifurcation stent implantation. Among the 88 iden-
tiﬁed target vessel MIs, 81 (92%) were CK-MB
elevation <10  upper limit of normal. Rates of Aca-
demic Research Consortium–deﬁned stent throm-
bosis (Tryton 0.6% vs. provisional 0.3%, p ¼ 1.00 [all
early stent thrombosis, between 1 and 30 days]) and
death (Tryton 1.2% vs. provisional 1.2%, p ¼ 1.00)
were similar and low in both groups (Table 3).
The occurrence of adverse events over the initial
9 months is shown in Online Figure 3. No signiﬁcant
interaction was detected in regard to the primary
endpoint and whether the procedure was performed
within or outside of the United States.
ANGIOGRAPHIC FINDINGS AT 9 MONTHS. At 9
months after randomization, the SB in-segment
diameter stenosis (secondary powered endpoint)
was lower in the bifurcation stent group compared
with the provisional group (31.6% vs. 38.6%, p ¼ 0.002
for superiority). No differences between groups were
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The primary endpoint (TVF) and its components (cardiac death [not shown because 0% in both groups], target vessel MI, and clinically driven
TVR), stratiﬁed by SB sizes. A signiﬁcant interaction was shown between treatment strategies and SB sizes ($2.25 mm vs. <2.25 mm per QCA
assessment) with respect to the occurrence of the primary endpoint of TVF (p for interaction ¼ 0.006) and target vessel MI (p for interaction ¼
0.02). MI ¼ myocardial infarction; OR ¼ odds ratio; QCA ¼ quantitative coronary angiography; SB ¼ side branch; TVF ¼ target vessel failure;
TVR ¼ target vessel revascularization.
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539seen in the rate of binary restenosis (diameter
stenosis $50%) in the MB or SB at follow-up (Table 4).
SIDE BRANCH ANALYSIS. Table 5 and the Central
Illustration show the rate of primary and secondary
powered endpoints in patients with larger SBs
(SB at baseline $2.25 mm by quantitative coronaryangiography [QCA], equivalent to w$2.5 by visual
estimate) compared with the patients with smaller SBs
(<2.25 mm by QCA), a post-hoc non–pre-speciﬁed
analysis. A signiﬁcant interaction was shown be-
tween treatment strategies and SB sizes ($2.25 mm
vs. <2.25 mm) in the occurrence of TVF (p for
TABLE 3 Clinical Outcomes at 9 Months
Tryton Stent
(N ¼ 355)
Provisional
(N ¼ 349) p Value
TVF* 60/345 (17.4) 43/337 (12.8) 0.11
Death 4/347 (1.2) 4/337 (1.2) 1.00
Cardiac 0/343 (0.0) 0/333 (0.0) —
Noncardiac 4/347 (1.2) 4/337 (1.2) 1.00
Target vessel MI 52/345 (15.1) 36/337 (10.7) 0.11
Q-wave 2/343 (0.6) 1/333 (0.3) 1.00
Non–Q-wave 50/345 (14.5) 34/337 (10.1) 0.08
Nontarget vessel MI 2/343 (0.6) 2/334 (0.6) 1.00
Q-wave 0/343 (0.0) 0/333 (0.0) —
Non–Q-wave 2/343 (0.6) 2/334 (0.6) 1.00
Modiﬁed ARC MI 54/345 (15.7) 38/338 (11.2) 0.09
Periprocedural PCI 47/345 (13.6) 34/336 (10.1) 0.19
Peri-CABG 1/343 (0.3) 0/333 (0.0) 1.00
Spontaneous 7/343 (2.0) 5/335 (1.5) 0.77
Sudden death 0/343 (0.0) 0/333 (0.0) —
Reinfarction 0/343 (0.0) 0/333 (0.0) —
Q-wave MI† 2/343 (0.6) 1/333 (0.3) 1.00
Non–Q-wave MI† 52/345 (15.1) 36/338 (10.7) 0.09
TVR 19/344 (5.5) 13/335 (3.9) 0.37
Clinically driven TVR 16/343 (4.7) 12/334 (3.6) 0.56
Nonclinically driven TVR 4/344 (1.2) 2/334 (0.6) 0.69
MB 14/343 (4.1) 10/334 (3.0) 0.54
SB 9/343 (2.6) 5/334 (1.5) 0.42
Non-TVR 13/343 (3.8) 12/333 (3.6) 1.00
Target lesion revascularization 17/344 (4.9) 11/335 (3.3) 0.34
Clinically driven target lesion
revascularization
14/343 (4.1) 10/334 (3.0) 0.54
Nonclinically driven target lesion
revascularization
3/344 (0.9) 2/334 (0.6) 1.00
MB 12/343 (3.5) 8/334 (2.4) 0.50
SB 9/343 (2.6) 5/334 (1.5) 0.42
ARC-deﬁned stent thrombosis
(deﬁnite, probable)
2/343 (0.6) 1/334 (0.3) 1.00
MB 2/343 (0.6) 1/334 (0.3) 1.00
SB 2/343 (0.6) 0/333 (0.0) 0.50
MACE (death, MI, emergent CABG,
clinically driven TLR)
65/349 (18.6) 45/340 (13.2) 0.06
Values are n/N (%). *Deﬁned as cardiac death, target vessel MI, or clinically driven TVR.
†Cumulative of target vessel, nontarget vessel, and undetermined vessel.
ARC ¼ Academic Research Consortium; MACE ¼ major adverse cardiac event(s); MB ¼ main
branch SB ¼ side branch; TLR ¼ target lesion revascularization; TVF ¼ target vessel failure;
TVR ¼ target vessel revascularization; other abbreviations as in Table 1.
TABLE 4 Angiographic Follow-Up at 9 Months
Tryton Stent
(N ¼ 158)
Provisional
(N ¼ 168) p Value
Quantitative angiographic
ﬁndings
MB
Reference vessel
diameter, mm
2.95  0.35 2.88  0.32 0.05
In-segment minimal
lumen diameter, mm
2.14  0.56 2.13  0.48 0.85
In-segment diameter
stenosis, %
27.77  15.87 26.02  14.01 0.29
In-stent minimal lumen
diameter, mm
2.47  0.54 2.44  0.43 0.58
In-stent diameter
stenosis, %
16.47  14.28 14.94  12.75 0.31
SB
Reference vessel
diameter, mm
2.29  0.29 2.24  0.31 0.10
In-segment minimal
lumen diameter, mm
1.56  0.56 1.36  0.38 <0.001
In-segment diameter
stenosis, %
31.57  22.91 38.63  16.16 0.002
In-stent minimal lumen
diameter, mm
1.67  0.62 — —
In-stent diameter
stenosis, %
26.72  25.44 — —
Binary restenosis
MB
In-segment 16/158 (10.1) 15/168 (8.9) 0.85
In-stent 7/158 (4.4) 3/167 (1.8) 0.21
SB
In-segment 35/155 (22.6) 45/168 (26.8) 0.44
In-stent 31/152 (20.4) — —
MB or SB
In-segment 44/156 (28.2) 56/168 (33.3) 0.34
In-stent 33/153 (21.6) — —
Values are mean  SD or n/N (%).
Abbreviations as in Table 3.
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540interaction ¼ 0.006) and target vessel MI (p for
interaction ¼ 0.02).
DISCUSSION
The main results of the TRYTON trial can be sum-
marized as follows. 1) A bifurcation 2-stent strategy in
true bifurcations compared with the standard 1-stent
provisional strategy did not meet the noninferiority
TVF endpoint, mainly because of more frequent
small periprocedural MIs. 2) Bifurcation stent use
was associated with a reduced stenosis of the SB
compared with the provisional approach at 9-monthfollow-up. 3) Both strategies were safe, with low
rates of stent thrombosis, cardiac death, and clinically
driven revascularization. 4) There was a disparity
between angiographic restenosis and clinically driven
TVR for both arms, indicating that SB angiographic
restenosis is uncommonly expressed clinically.
5) A post-hoc analysis of SB size identiﬁed a strong
interaction in the occurrence of the primary endpoint
(TVF), showing lack of beneﬁt of the bifurcation
2-stent strategy in smaller SBs and potential beneﬁt in
larger SBs.
The present study demonstrates and conﬁrms the
safety of the provisional approach as the primary
strategy when facing complex bifurcation lesions.
The need for additional stenting for bailout situations
with the provisional approach was relatively infre-
quent (8% for the provisional group vs. 2.9% for the
bifurcation stent group). The bifurcation stent
approach was also safe, with a high implantation
TABLE 5 Primary and Secondary Endpoints at 9 Months Stratiﬁed by
Side Branch Size
Tryton Stent Provisional p Value
Side branches <2.25 mm N ¼ 208 N ¼ 205
TVF* 44/203 (21.7) 20/195 (10.3) 0.002
Cardiac death 0/201 (0.0) 0/194 (0.0) —
Target vessel MI 39/203 (19.2) 18/195 (9.2) 0.006
Clinically driven TVR 11/201 (5.5) 6/195 (3.1) 0.32
In-segment SB % diameter stenosis† 32.35  23.26 36.79  14.99 0.13
Side branches $2.25 mm N ¼ 146 N ¼ 143
TVF* 16/141 (11.3) 22/141 (15.6) 0.38
Cardiac death 0/141 (0.0) 0/139 (0.0) —
Target vessel MI 13/141 (9.2) 17/141 (12.1) 0.56
Clinically driven TVR 5/141 (3.5) 6/139 (4.3) 0.77
In-segment SB % diameter stenosis‡ 30.43  22.53 40.61  17.20 0.004
Values are n/N (%) or mean  SD. Nonhierarchical intention-to-treat population. *TVF is deﬁned
as cardiac death, target vessel MI, or clinically driven TVR. †From the angiographic cohort: n ¼ 94
for Tryton group and n ¼ 87 for provisional group. ‡From the angiographic cohort: n ¼ 64
for Tryton group and n ¼ 81 for provisional group.
Abbreviations as in Tables 1 and 3.
J A C C V O L . 6 5 , N O . 6 , 2 0 1 5 Généreux et al.
F E B R U A R Y 1 7 , 2 0 1 5 : 5 3 3 – 4 3 Bifurcation Stent Versus Provisional Stenting
541success rate (>96%) and no safety concerns (cardiac
death, stent thrombosis) compared with the provi-
sional approach.
Despite lower SB diameter stenosis in the bifurca-
tion stent group compared with the provisional group
(31.6% vs. 38.6%) at 9-month follow-up, no differ-
ences were seen related to the binary restenosis rate
(deﬁned as diameter stenosis of $50%; 22.6% vs.
26.8%), illustrating that most of the SB lesions at
follow-up were <50% stenosis. Moreover, an impor-
tant discrepancy between the angiographic rate of
binary restenosis and the need for subsequent clini-
cally driven revascularization (w4% of the entire
cohort) highlights the clinical impression that mod-
erate lesions in the SB ostium, especially when short
(w4 to 5 mm in the current study), are rarely clinically
signiﬁcant. Physiological assessment of the SB (via
fractional-ﬂow reserve performed post-procedure)
rather than anatomic assessment (angiography)
would have potentially reduced this discrepancy and
increased the correlation with clinical outcomes
(22–24).
Small periprocedural CK-MB elevations (w90%
<10  UNL CK-MB elevation) occurred more
frequently with a 2-stent strategy and dominated the
primary clinical endpoint (TVF). These ﬁndings are
consistent with the results of 2 recent meta-analyses,
including all current randomized trials comparing the
provisional approach with a 2-stent technique,
showing no differences in terms of death, need for
revascularization, or stent thrombosis between the 2
strategies, but an increase in periprocedural MIs (2,3).
More aggressive lesion preparation, increased coro-
nary instrumentation, especially in smaller SBs, and
longer procedural times may explain these results.
However, this increase in periprocedural MIs did not
result in clinically signiﬁcant adverse events, such as
cardiac death and the need for revascularization.
Likewise, favorable angiographic results of the bi-
furcation stent strategy in SB diameter stenosis at
9-month follow-up also did not result in clinical
beneﬁt. These ﬁndings illustrate the well-known
discrepancy between angiography (diameter stenosis
severity) and biologic (CK-MB and troponin elevation)
surrogate endpoints compared with hard clinical
endpoints in coronary angioplasty clinical trials, if a
certain threshold level of the surrogates is not reached
(25–29).
STUDY LIMITATIONS. The TRYTON bifurcation
study has several limitations that should be
acknowledged. Only 41% of the study population
met the entry criteria for SB diameter size ($2.25
mm per QCA, equivalent to w$2.5 per visualestimate). Although providing meaningful insights
into the clinical relevance of treating SBs with a
dedicated SB stent, the inclusion of w60% of pa-
tients not meeting the inclusion criteria for SB
diameter reduced our capacity to demonstrate the
value of a dedicated bifurcation stent strategy in
true bifurcations with SBs of signiﬁcant size. The
large SB ﬁndings in the post-hoc analysis are
intriguing and hypothesis generating, and will
require further investigation. Only short lesions (#5
mm) of the SB were included in the TRYTON trial.
The beneﬁt of the bifurcation stent in SB lesions >5
mm, potentially facilitating the delivery of a second
DES (or bioresorbable scaffold) in the SB, remains to
be established. The current version of the bifurca-
tion stent is a non-DES; a drug-eluting platform
may have led to different results (30–34). The
protocol-mandated selection criteria excluded
important lesion subsets, such as bifurcation lesions
involving the left main artery, where the use of a
dedicated bifurcation stent approach, given the
larger jeopardized myocardial mass, could be of
greater beneﬁt. Because bifurcation stent implanta-
tion was a relatively new procedure (especially in
the United States) and relatively few patients were
treated per site (United States, mean of 6.3 patients
per site; Europe, mean of 16 patients per site),
learning curve issues must be considered. This is
compounded by the realization that optimal im-
plantation technique is mandatory to achieve the
full advantage of the bifurcation stent. Finally, the
quantitative angiographic analyses for bifurcation
lesions in this manuscript represent conventional
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
Symptomatic coronary stenosis frequently involves
arterial branch points, and percutaneous interventions
on these bifurcation lesions are associated with a
relatively high risk of adverse events.
TRANSLATIONAL OUTLOOK: Future studies
comparing dedicated bifurcation devices with other
novel stent technologies (e.g., bioresorbable scaf-
folds) will better deﬁne optimum approaches to
management of patients with bifurcation lesions
undergoing percutaneous revascularization.
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542single-vessel methodology, and newer bifurcation
algorithms showed somewhat different results (35)
(Online Table 5).
CONCLUSIONS
On the basis of failure to achieve the noninferiority
primary clinical endpoint, provisional stenting should
remain the preferred strategy in the treatment of
non–left main true coronary bifurcation lesions.
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